Amicus Therapeutics, Inc. (0HF9.L) Comparison with companies in other sectors?

Amicus Therapeutics, Inc. has a share price of 293.13M. You can analyze Amicus Therapeutics, Inc. (0HF9.L) competitors across different market sectors through stock heatmaps.

What are 0HF9.L's NET and operating margins?

Amicus Therapeutics, Inc. (0HF9.L) operating margin is around 0.04, and net profit margin is approximately -0.07 as of the latest reports.

In what way does 0HF9.L's earnings per share (EPS) trend reflect its financial momentum?

Amicus Therapeutics, Inc. (0HF9.L) EPS is -0.97 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Amicus Therapeutics, Inc. is -7.69, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Amicus Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Amicus Therapeutics, Inc. like P/E which is -60.39, P/B which is 11.26, and PEG which is 2.44. Compare them with sector averages to evaluate if the stock is priced fairly.

Amicus Therapeutics, Inc.

0HF9.L•LSE

Healthcare

Medical - Pharmaceuticals

£7.49

£-0.04(-0.60%)

Amicus Therapeutics, Inc. (0HF9.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.97

P/E Ratio

-7.69

ROE

-0.20%

Net Margin

-0.07%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.19B

Shares OutstandingTotal number of shares issued

$293.13M

Book Value/ShareNet worth per share

$0.66

Revenue/ShareAnnual revenue per share

$1.85

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.973

Net MarginNet income as percentage of revenue

-6.67%

Operating MarginOperating income as percentage of revenue

3.54%

ROEReturn on shareholders' equity

-19.77%

ROAReturn on total assets

-4.67%

ROCEReturn on capital employed

3.12%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.16

Cash/ShareCash and equivalents per share

$0.75

FCF YieldFree cash flow as percentage of market cap

-2.13%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0HF9.LFinancial Ratios Analysis details for 0HF9.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0HF9.LSector Benchmarking details for 0HF9.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Amicus Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Amicus Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Amicus Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Amicus Therapeutics, Inc.

For Amicus Therapeutics, Inc., essential financial indicators include EPS -0.97, PE -7.69, and ROE -0.20. These key ratios reveal insights into Amicus Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Amicus Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Amicus Therapeutics, Inc.

Metrics like Net Margin -6.67% and ROA -4.67% shed light on how well Amicus Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Amicus Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Amicus Therapeutics, Inc.

Using ratios such as P/B Ratio 11.26 and PEG Ratio 2.44, investors can assess whether Amicus Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Amicus Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Amicus Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 2.17 and Cash Flow $-0.16, provide a snapshot of Amicus Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Amicus Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Amicus Therapeutics, Inc.

Investing in Amicus Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Amicus Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;